drugset / Trial / NCT02344940

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer

NCT02344940

Phase 4 Completed 104 enrolled Shanghai Jiao Tong University School of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the safety of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer by monitoring gynecological abnormality,blood lipid level,hepatic abnormality,estrogen level and perimenopausal symptoms.

Timeline

Start
2014-12
Primary completion
2018-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tamoxifen Small molecule 10 mg
Subject Toremifene Small molecule 60 mg

Indications